Zurcher Kantonalbank (Zurich Cantonalbank) Entrada Therapeutics, Inc. Transaction History
Zurcher Kantonalbank (Zurich Cantonalbank)
- $33.8 Billion
- Q1 2025
A detailed history of Zurcher Kantonalbank (Zurich Cantonalbank) transactions in Entrada Therapeutics, Inc. stock. As of the latest transaction made, Zurcher Kantonalbank (Zurich Cantonalbank) holds 746 shares of TRDA stock, worth $5,669. This represents 0.0% of its overall portfolio holdings.
Number of Shares
746Holding current value
$5,669% of portfolio
0.0%Shares
1 transactions
Others Institutions Holding TRDA
# of Institutions
111Shares Held
28.7MCall Options Held
8.2KPut Options Held
2.3K-
Baker Bros. Advisors LP New York, NY4.87MShares$37 Million0.52% of portfolio
-
5 Am Venture Management, LLC San Francisco, CA4.41MShares$33.5 Million27.61% of portfolio
-
Mpm Asset Management LLC Cambridge, MA4.38MShares$33.3 Million57.03% of portfolio
-
Price T Rowe Associates Inc Baltimore, MD2.74MShares$20.8 Million0.0% of portfolio
-
Janus Henderson Group PLC London, X02.12MShares$16.1 Million0.01% of portfolio
About Entrada Therapeutics, Inc.
- Ticker TRDA
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 31,368,500
- Market Cap $238M
- Description
- Entrada Therapeutics, Inc., a biotechnology company, develops endosomal escape vehicle (EEV) therapeutics for the treatment of multiple neuromuscular diseases. Its endosomal escape vehicle platform develops a portfolio of oligonucleotide, antibody, and enzyme-based programs. The company's lead product candidate is ENTR-601-44, which is in precli...